The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to pose a global public health threat. Effective and rapid serological assays are needed to provide valuable information about acute and past viral infections. Using the receptor-binding domain of the SARS-CoV-2 spike protein 1 antigen and a highly sensitive detection technology, termed magnetic modulation biosensing (MMB), we demonstrate a quantitative and rapid SARS-CoV-2 IgG antibody test with high sensitivity and specificity compared with the gold standard ELISA test. The improved analytical and clinical sensitivity of the MMB-based assay can help clinical laboratories provide critical information in a timely manner and monitor the spread of the disease.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.